Manufacturer record
Cureza Healthcare Pvt. Ltd: regulatory record
Last checked 20 September 2026. Source: CDSCO monthly NSQ alerts and state drug-testing laboratories
6 batches manufactured by Cureza Healthcare Pvt. Ltd (Madhya Pradesh) were declared Not of Standard Quality between November 2023 and July 2026. Records are batch-specific findings by government laboratories as published in CDSCO's monthly alerts; where a company has stated that a flagged batch was counterfeit, that statement is noted when reported.
Records by type
6 records linked to Cureza Healthcare Pvt. Ltd in the datasets we hold. A zero means nothing is on record in those datasets, not that nothing ever happened. What the labels mean.
CDSCO drug alerts: Not of Standard Quality and spurious drugs
Scope. A company appearing here is not a finding that its products are unsafe. Regulatory actions can apply to one batch, one formulation, one period or one state. Always check the linked government document for the current position, and tell us if something is out of date. How we label records.
Flagged batches per year
All flagged batches
| Product | Batch | Reason declared NSQ | Tested by | Alert |
|---|---|---|---|---|
| Glimepiride Tablets IP 2mg | CHPLT1027Mfg 2025-12 · Exp 2027-11 | The Sample does not Comply with IP Requirements for the Dissolution Test.Dissolution | FDAL, Chhatrapati SambhajinagarState lab | Jul 2026 |
| Calcium and Vitamin D3 Tablets IP | CH26T203Mfg 2026-05 · Exp 2027-10 | Dissolution :-(Calcium) Does not complies with IP limit as 3 out of 6 tablets are less than Q-25% Also some tablets can't even dissolve completely within the prescribed time limit.Dissolution | Govt Analyst PunjabState lab | Jul 2026 |
| Calcium and Vitamin D3 Tablets IP(Calse-D3) | CHPLT562Mfg 2024-12 · Exp 2026-05 | Dissolution and AssayAssay | CDL, KolkataCDSCO lab | Oct 2025 |
| Calcium and Vitamin D3 Tablets IP (Calse-D3) | CHPLT538Mfg 2024-12 · Exp 2026-05 | Dissolution and AssayAssay | CDL, KolkataCDSCO lab | Oct 2025 |
| Fluconazole Tablets IP 150 mg (Flucse - 150) | CHT23621Mfg 2024-02 · Exp 2026-01 | Uniformity of weightUniformity of weight/content | CDTL MumbaiCDSCO lab | Sep 2024 |
| Telmisartan Tablets I.P. 40 mg. (Telmisev- 40) | CHT22352Mfg 2022-12 · Exp 2024-11 | DissolutionDissolution | RDTL GuwahatiState lab | Nov 2023 |
Right of reply. Manufacturers may submit a response or a laboratory re-test result; it is published unedited alongside this record. Submit a response.